A trial looking at gemcitabine with MK-0752 to treat pancreatic cancer

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Pancreatic cancer




Phase 1

This trial is looking at giving MK-0752 with gemcitabine to treat pancreatic cancer. This trial is supported by Cancer Research UK.

Doctors often use gemcitabine to treat pancreatic cancer. To try and improve treatment for pancreatic cancer doctors have combined gemcitabine with other drugs.

Laboratory studies Open a glossary item have shown that MK-0752 may be able to help people with cancer. It works by decreasing the amount of a protein that some cancer cells need to grow and divide.

The researchers think that combining MK-0752 with gemcitabine may be better than gemcitabine alone.

The aims of this trial are to find out

  • The highest, and safest, dose of MK-0752 and gemcitabine that you can have together
  • The side effects of MK-0752 and gemcitabine
  • How to manage these side effects
  • What happens to MK-0752 in the body
  • What effect the combination of MK-0752 and gemcitabine has on pancreatic cancer

Who can enter

You can enter this trial if you

  • Have the most common type of pancreatic cancer (adenocarcinoma) that has grown outside the pancreas into the nearby large blood vessels (stage 3) or has spread to another part of your body (stage 4)
  • Have a tumour that can be measured on a CT scan, MRI scan or X-ray
  • Can have a small piece of tissue (biopsy Open a glossary item) taken from your tumour (if the researchers need it) - your doctor can advise about this
  • Have satisfactory blood test results
  • Are willing to use reliable contraception if there is a chance that you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if

  • Your cancer has spread to the brain (unless your symptoms have not changed in the last 4 weeks and you have been taking the same dose of steroids for a while – your doctor can advise about this
  • You have had hormone therapy, immunotherapy or radiotherapy (you may join the trial if the radiotherapy was only to control symptoms)
  • You are still having side effects from previous treatments – your doctor can advise about this
  • You are taking a drug as a part of another clinical trial
  • You have had major surgery to the chest or tummy (abdomen) and are not better
  • You are taking a drug called warfarin to stop blood clots (unless you are able to change to a similar drug called heparin – your doctor can advise about this)
  • You are known to be HIV, hepatitis B or hepatitis C positive
  • You have a major heart problem or a history of decreased blood supply to the heart or irregular heart beats
  • You have another cancer, unless it has been treated and there has been no sign of it (complete remission Open a glossary item) for at least 5 years (you may join the trial if you have in situ carcinoma of the cervix and basal cell or squamous cell skin cancer)
  • You have another medical condition that could affect you taking part in this trial

Trial design

This is a phase 1 trial. It will recruit about 56 people in the UK. Everyone will have MK-0752 and gemcitabine.

The first 2 patients taking part will have the lowest dose of MK-0752. If they don’t have any serious side effects, the next 2 patients will have a higher dose. And so on, until they find the best dose to give. This is called a ‘dose escalation study’.

At each dose of MK-0752, the researchers will use 2 doses of gemcitabine. One dose will be slightly lower than the other.

MK-0752 is a capsule. You take it once a week. To start with, you have 2 weeks of taking MK-0752 only. Then you start having it with gemcitabine.

You have gemcitabine once a week for 3 weeks and 1 week of no gemcitabine. You have gemcitabine through a drip into a vein (intravenous) over 30 minutes.

Each 4 week period is called a cycle of treatment.

You can have up to 12 cycles of treatment as long as it is helping you and you have no serious side effects.

Before you start treatment and at the 2nd dose of MK-0752, the researchers will take a small piece of  tumour tissue sample (biopsy), if you are one of the people who need to give one. The researchers will also take a few hairs from your head when you start taking MK-0752. This is to see how MK-0752 is working in your body.

Hospital visits

You will see the doctor and have some tests before taking part in this trial. These tests include

  • Physical examination
  • Blood tests
  • Urine test
  • Heart trace (ECG Open a glossary item)
  • CT scan
  • Pregnancy test (if appropriate)

During treatment you see the doctor every week to have

  • Physical examination
  • Blood tests
  • Urine test
  • CT scan (every 8 weeks)

After taking MK-0752 for 2 weeks, you may have a  biopsy.

Side effects

MK-0752 and gemcitabine have many side effects in common including

Other side effects of gemcitabine can include

But this is the first time MK-0752 and gemcitabine have been given in combination and there may be side effects we do not know about.

We have more information about gemcitabine.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Duncan Jodrell

Supported by

Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
Merck & Co. Inc
NIHR Clinical Research Network: Cancer

Cancer Research UK trial number

This is Cancer Research UK trial number CRUKD/10/028.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 5032

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think